Welcome to our dedicated page for electroCore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on electroCore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore, a commercial-stage bioelectronic medicine company (NASDAQ: ECOR), announced its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The presentation is scheduled for January 10, 2022, at 7:00 am ET. Investors can register for the conference HERE.
A webcast replay will be available post-conference on the investor section of the company's website.
electroCore, Inc. (NASDAQ: ECOR) has secured exclusive distribution agreements for its gammaCore Sapphire™ non-invasive vagus nerve stimulator in several territories. The agreements are with Melidonia Health Services for Cyprus, Cyrus Medical Technologies for the UAE and Oman, and Express Medical Solutions LLC for Saudi Arabia and Bahrain. The agreements with Melidonia, Cyrus, and Medexsol have initial terms of three to five years.
These partnerships are part of electroCore's global expansion strategy to enhance accessibility to its therapeutic product for headache patients. Regulatory clearances are pending before sales can commence.
electroCore, a bioelectronic medicine company, has launched an e-commerce shop in the UK for its gammaCore Sapphire™ device, designed to treat menstrual migraines. The online platform allows patients to complete a healthcare questionnaire, receive product delivery, and receive training via video calls. Karly Hoggard, Director of Global Commercial Development, emphasized the importance of accessibility for women suffering from migraines, noting that 60% of them experience menstrual-related symptoms. The gammaCore device is FDA cleared and CE-marked for various headache treatments.
electroCore, a commercial-stage bioelectronic medicine company, provided an update on its clinical research using gammaCore (nVNS) to treat Post Traumatic Stress Disorder (PTSD). A recent study demonstrated a 31% reduction in PTSD symptoms among 20 patients after three months of treatment with nVNS compared to a sham device. The company is currently conducting two randomized, sham-controlled clinical trials to further evaluate the efficacy of nVNS in treating PTSD. CEO Dan Goldberger highlighted gammaCore's potential as a safe and effective treatment, with regulatory updates expected in 2022.
electroCore (NASDAQ: ECOR) announced the issuance of U.S. Patent No. 11,191,953 by the USPTO, focused on treating symptoms of stroke and transient ischemic attack (TIA) through non-invasive electrical stimulation. This patent bolsters research in stroke treatment, a leading cause of death and disability globally. Earlier this year, the TR-VENUS study reported full enrollment for investigating non-invasive vagus nerve stimulation (nVNS) for acute stroke treatment. The patent aims to enhance the application of electroCore’s technology to mitigate stroke impacts, with ongoing trials expected to shed light on its efficacy.
electroCore, a bioelectronic medicine company (NASDAQ: ECOR), will host virtual one-on-one meetings at the Canaccord Genuity MedTech & Diagnostics Forum on November 18, 2021. The management team aims to discuss its non-invasive vagus nerve stimulation therapy platform designed for treating migraines and cluster headaches, including acute and preventive treatments. Stakeholders interested in a meeting should contact their Canaccord Genuity representative to arrange the details. For more information, visit www.electrocore.com.
electroCore reported third quarter 2021 revenue of $1.5 million, a significant increase of 17% sequentially and 38% year-over-year. The gross margin expanded to 76%, and cash reserves reached approximately $39.0 million. Despite a GAAP net loss of $4.0 million, the company announced reduced operating expenses and a confidence in growth prospects despite pandemic impacts on its markets. The company raised about $18.8 million through a public offering, ensuring sufficient funds for planned operations over the next year.
electroCore, Inc. (NASDAQ: ECOR) will report its financial results for Q3 2021 on November 4, 2021, following the market close. A conference call will be held at 4:30 PM ET to discuss the results. The company focuses on non-invasive vagus nerve stimulation therapies aimed at treating various neurological conditions including migraines and cluster headaches. With a commercial-stage product line, electroCore aims to improve patient outcomes.
On October 20, 2021, electroCore, Inc. (Nasdaq: ECOR) announced a peer-reviewed study in the British Journal of Healthcare Management evaluating prescribing trends for gammaCore in treating cluster headaches in England from April 2019 to 2020. The study involved 655 patients, revealing that 46.3% continued treatment with at least one refill and 30.9% required two or more refills. This suggests a durable benefit of gammaCore's non-invasive vagus nerve stimulation (nVNS) therapy. The NHS’s reimbursement program and favorable cost-saving implications were also highlighted.
electroCore has received an amended Medical Device License from Health Canada for gammaCore nVNS to treat migraine in adolescents aged 12-17. This expansion allows for both acute and preventive treatment of migraine, providing a non-drug option in a field with limited treatments for young patients. The decision is based on positive data, including a study showing 46.8% attack resolution without additional medication. The device is now available in Canada through RSK Medical Inc., enhancing options for managing primary headache disorders.